Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Could Forest's DDMAC Letter For Off-Label Promotion Doom CEO Solomon?

This article was originally published in The Pink Sheet Daily

Executive Summary

A physician complained to FDA's "Bad Ad" program about a Forest Laboratories sales representative's off-label claims for the fibromyalgia drug Savella.
Advertisement

Related Content

Daliresp Sales Pitch Draws FDA Letter After Forest Fails To Heed Advisory Comments
Sunovion Sales Rep Draws FDA Promotional Letter For Declaring Broader Latuda Label Inevitable
"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One
"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One
DDMAC's "Bad Ad" Enforcement Often Requires Affidavits
DDMAC's "Bad Ad" Enforcement Often Requires Affidavits
How Broadly Will OIG Enforce Its Exclusion Powers? Possible Action Against Forest CEO Offers A Lesson
Forest Admits To Knowingly Obstructing FDA Inspection In Guilty Pleas On Levothroid, Celexa Marketing
Forest Admits To Knowingly Obstructing FDA Inspection In Guilty Pleas On Levothroid, Celexa Marketing
Antibiotic Promotions Can't Rely On In Vitro Claims, Even If Labeling Might

Topics

Advertisement
UsernamePublicRestriction

Register

PS072317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel